ATE396737T1 - Prophylaxe, behandlung und prognose/überwachung von sepsis und septischem schock - Google Patents

Prophylaxe, behandlung und prognose/überwachung von sepsis und septischem schock

Info

Publication number
ATE396737T1
ATE396737T1 AT03741651T AT03741651T ATE396737T1 AT E396737 T1 ATE396737 T1 AT E396737T1 AT 03741651 T AT03741651 T AT 03741651T AT 03741651 T AT03741651 T AT 03741651T AT E396737 T1 ATE396737 T1 AT E396737T1
Authority
AT
Austria
Prior art keywords
sepsis
apoci
prognosis
monitoring
treatment
Prior art date
Application number
AT03741651T
Other languages
English (en)
Inventor
Patrick Rensen
Aloysius Havekes
Original Assignee
Tno
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tno filed Critical Tno
Application granted granted Critical
Publication of ATE396737T1 publication Critical patent/ATE396737T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT03741651T 2002-06-28 2003-06-27 Prophylaxe, behandlung und prognose/überwachung von sepsis und septischem schock ATE396737T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL1020962A NL1020962C2 (nl) 2002-06-28 2002-06-28 Therapie en prognose/monitoring bij sepsis en septische shock.

Publications (1)

Publication Number Publication Date
ATE396737T1 true ATE396737T1 (de) 2008-06-15

Family

ID=29997579

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03741651T ATE396737T1 (de) 2002-06-28 2003-06-27 Prophylaxe, behandlung und prognose/überwachung von sepsis und septischem schock

Country Status (8)

Country Link
US (2) US9176153B2 (de)
EP (1) EP1517696B1 (de)
JP (1) JP5093830B2 (de)
AT (1) ATE396737T1 (de)
AU (1) AU2003280523A1 (de)
DE (1) DE60321341D1 (de)
NL (1) NL1020962C2 (de)
WO (1) WO2004002518A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040096917A1 (en) * 2002-11-12 2004-05-20 Becton, Dickinson And Company Diagnosis of sepsis or SIRS using biomarker profiles
DE10343815A1 (de) * 2003-09-22 2005-04-14 B.R.A.H.M.S Ag Verfahren zur Diagnose von Erkrankungen unter Bestimmung von Apolipoprotein C-I, und dessen Verwendung in der Therapie von Erkrankungen
CA2745189A1 (en) * 2008-12-22 2010-07-01 The Children's Research Institute Methods for detection of sepsis
EP3845904A1 (de) * 2010-06-03 2021-07-07 Idexx Laboratories, Inc. Marker für nierenerkrankung
CN105652019B (zh) * 2016-02-22 2017-10-20 西安交通大学 一种孤独症血清多肽标志物apoc1‑a及其应用
KR102424496B1 (ko) 2016-03-02 2022-07-25 아이덱스 래보러토리즈, 인코포레이티드 신장 질환 및 치주 질환의 검출 및 진단을 위한 방법 및 조성물
IL286317B1 (en) * 2019-03-13 2026-07-01 Fundaci?N Para La Formaci?N E Investigaci?N Sanitarias De La Regi?N De Murcia Ffis A method for obtaining clinical data in patients suffering from inflammatory disease in vitro
CN111208305B (zh) * 2020-02-16 2023-04-25 重庆翼锋生物科技有限公司 Hbp和pct在败血症诊断试剂制备中的用途
CN117517679A (zh) * 2023-11-23 2024-02-06 重庆医科大学附属儿童医院 载脂蛋白h作为生物标志物在诊断、预测或监测儿童脓毒症的进展中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594113A (en) * 1988-06-23 1997-01-14 Associates Of Cape Cod, Inc. Endotoxin binding and neutralizing protein and uses thereof
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) * 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
IL131118A0 (en) * 1999-07-26 2001-01-28 Trellis Photonics Ltd Electroholographic wavelength selective photonic switch for wdm routing

Also Published As

Publication number Publication date
US9176153B2 (en) 2015-11-03
DE60321341D1 (de) 2008-07-10
WO2004002518A1 (en) 2004-01-08
EP1517696A1 (de) 2005-03-30
US20060111283A1 (en) 2006-05-25
EP1517696B1 (de) 2008-05-28
NL1020962C2 (nl) 2003-12-30
AU2003280523A1 (en) 2004-01-19
JP2005537243A (ja) 2005-12-08
US20160030516A1 (en) 2016-02-04
JP5093830B2 (ja) 2012-12-12

Similar Documents

Publication Publication Date Title
Bennick et al. The role of human salivary acidic proline-rich proteins in the formation of acquired dental pellicle in vivo and their fate after adsorption to the human enamel surface
McMullen et al. Location of the disulfide bonds in human coagulation factor XI: the presence of tandem apple domains
Shimokawa et al. Sequence and Biological Activity of Catrocollastatin-C: A Disintegrin-Like/Cysteine-Rich Two-Domain Protein fromCrotalus atroxVenom
Campese et al. Concentration and fate of histatins and acidic proline-rich proteins in the oral environment
JP7546622B2 (ja) 活性薬剤の経口投与のための製剤
Johnson et al. Effect of donor age on the concentrations of histatins in human parotid and submandibular/sublingual saliva
ATE327764T1 (de) Hmg1 antagonisten zur behandlung von entzündungen
DE60009896D1 (de) Neue indikationen für mannan-binding lectin (mbl) zur behandlung von immungeschwächten patienten
DE60321341D1 (de) Prophylaxe, behandlung und prognose/überwachung von sepsis und septischem schock
ATE269978T1 (de) Verfahren zur bestimmung der prognose eines patienten mit einer neurologischen krankheit
Omori-Satoh et al. The antihemorrhagic factor, erinacin, from the European hedgehog (Erinaceus europaeus), a metalloprotease inhibitor of large molecular size possessing ficolin/opsonin P35 lectin domains
Taira et al. Statherin-derived peptide protects against intrinsic erosion
Jainkittivong et al. The relationship between salivary histatin levels and oral yeast carriage
BR9808804A (pt) Processos para tratar um indivìduo para melhorar o funcionamento do trato gastrointestinal superior incluindo o esÈfago e o estÈmago, para tratar um indivìduo para proliferar o tecido do trato gastrointestinal superior, para identificar peptìdeos utilizável para tratar condições inflamatórias, para identificar peptìdeos, utilizável para evitar ou melhorar as condições inflamatórias, utilizável para identificar peptìdeos capazes de proliferar tecido do trato gastrointestinal superior, para tratar profilaticamente um indivìduo, para melhorar o crescimento do tecido do trato gastrointestinal superior em um mamìfero, e para tratar um indivìduo para melhorar o funcionamento do trato gastrointestinal superior, kit, processos para promover o crescimento de tecido do trato gastrointestinal superior ou células, para tratar um paciente para restaurar o trato gastrointestinal superior, para determinar a atividade de um hormÈnio quando usado em combinação com glp-2, para tratar um indivìduo tendo úlceras peptìdicas
Gusman et al. Human salivary gland-specific daily variations in histatin concentrations determined by a novel quantitation technique
Laurberg Tranexamic acid (Cyklokapron) in chronic urticaria: a double-blind study
FR2861731B1 (fr) Nouvelle proteine de fixation du phosphate, compositions pharmaceutiques la contenant et ses utilisations
Aguirre et al. Levels of salivary cystatins in periodontally healthy and diseased older adults
Bee et al. Novel in vitro assays for assessing the haemorrhagic activity of snake venoms and for demonstration of venom metalloproteinase inhibitors
Chippaux et al. Study of the efficacy of the black stone on envenomation by snake bite in the murine model
Rikimaru et al. Relationship between endothelin-1 and interleukin-1β in inflamed periodontal tissues
Cochran et al. Case reports of envenomation and venom composition differences between two Arizona populations of the Southwestern Speckled Rattlesnake, Crotalus pyrrhus (Cope, 1867)
Ferguson et al. Investigation of coagulopathy in three cases of tiger snake (Notechis ater occidentalis) envenomation
DE60015135D1 (de) Prolaktin freisetzendes peptid und verwendung zur behandlung von schmerzen
Shinde et al. Wound healing in dental implant surgery in patients with or without antibiotic prophylaxis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1517696

Country of ref document: EP